Medifast, Inc. — Q3 2023 Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2023. Medifast sells health and wellness products and plans primarily through its OPTA VIA brand and independent Coaches.
Financial performance
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | $235.9 million | $390.4 million | $881.0 million | $1,261.3 million |
| Gross profit / margin | $177.4 million / 75.2% | $282.8 million / 72.5% | $634.5 million / 72.0% | $906.8 million / 71.9% |
| Operating income / margin | $25.5 million / 10.8% | $48.2 million / 12.3% | $117.7 million / 13.4% | $152.2 million / 12.1% |
| Net income | $23.1 million | $36.2 million | $93.4 million | $117.1 million |
| Diluted EPS | $2.12 | $3.27 | $8.55 | $10.30 |
| Operating cash flow | Not separately presented for the quarter | $137.1 million | $142.8 million |
Liquidity and capital
- At September 30, 2023, cash and cash equivalents were $112.8 million and investment securities were $45.0 million, totaling $157.8 million in cash and investments. Working capital was $114.2 million.
- Total liabilities were $127.0 million, including $22.3 million of lease obligations. The company had no borrowings under its $225 million revolving credit facility and reported compliance with its covenants. The facility matures in April 2026.
- For the nine months, cash used in investing was $50.3 million, primarily reflecting $44.8 million of investment-security purchases. Cash used in financing was $61.9 million, including $55.0 million of dividends paid and $3.6 million of stock repurchases.
- The company declared a $1.65-per-share quarterly dividend in September, payable in November 2023. Future dividends and repurchases remain subject to board discretion.
Material changes and drivers
- Revenue fell 39.6% in Q3 and 30.2% for the nine-month period. Management attributed the decline primarily to fewer active earning Coaches and lower revenue per Coach. Active earning Coaches declined to approximately 47,100 from 66,200 year over year; average Q3 revenue per Coach fell to $5,008 from $5,897.
- Q3 gross margin improved 270 basis points, which management attributed to inventory-management and distribution efficiencies and lower supply-chain costs. Nine-month gross margin was broadly stable, with efficiencies partly offset by inflation in ingredients, shipping and labor.
- SG&A declined in dollars as Coach compensation decreased with lower volume and cost initiatives advanced. However, Q3 SG&A rose to 64.4% of revenue from 60.1%, reflecting lower fixed-cost absorption and investment in research related to medically supported weight loss. Nine-month SG&A declined to 58.7% of revenue from 59.8%.
- Q3 operating margin contracted to 10.8% from 12.3%; nine-month operating margin increased to 13.4% from 12.1%.
- During Q1, a change in customer terms moved revenue recognition from customer receipt to delivery to the shipping carrier. The change increased Q1 2023 revenue by approximately $9.1 million and operating income by $2.8 million.
Outlook, commentary and risks
- The filing provides no quantified revenue, earnings or margin guidance. Management said it expects future cash requirements, if any, to be funded from operating cash flow and financing activities.
- Initiatives include the Fuel for the Future cost and efficiency program, exit from Hong Kong and Singapore effective July 1, 2023, and investment in technology, digital capabilities and product expansion. OPTA VIA ACTIVE supplements launched in September; additional products were expected in 2024. Management said the line targets new customer groups and expands the company into sports nutrition.
- The company is exploring partnerships combining its Coach-guided program with clinician-supported weight loss, including GLP-1 medications, through a small pilot. It also began Spanish-language marketing efforts and anticipated a broader U.S. Hispanic-market effort in 2024. These are initiatives, not assured growth outcomes.
- Management cited consumer-spending uncertainty, inflation and commodity, labor and supply-chain costs as risks. It said the Ukraine war and Gaza conflict had not materially affected the business to date, while noting continued uncertainty. Legal matters arise in the ordinary course; the company did not expect them to have a material adverse effect, though outcomes cannot be predicted.
- Management reversed $1.4 million of share-based compensation expense in the first nine months after determining that 2022 performance-based awards would not reach their minimum performance threshold. The Q3 effective tax rate was 12.9%, versus 24.5% a year earlier, primarily due to tax benefits for inventory donations, R&D credits and lower state taxes.
Key facts for investors to verify
- Whether Coach count and productivity stabilize or continue to decline, and how customer-acquisition trends develop.
- Whether new products, medically supported weight-loss offerings and Hispanic-market efforts generate measurable demand and offset core-business weakness.
- Whether cost savings and supply-chain efficiencies can sustain margins amid inflation and lower sales volumes.
- The effects of the revenue-recognition change on period comparisons, and the sustainability of the unusually lower Q3 effective tax rate.
- Dividend and repurchase capacity, covenant compliance and liquidity as operating results evolve; confirm any subsequent developments after September 30, 2023.